Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

85 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
GL
Novartis: positive data for malaria treatment
CF
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
GL
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
GL
Novartis Scemblix shows superior major molecular response rates vs. standard of care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
AQ
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
GL
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy
AQ
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
GL
Transcript : Novartis AG - Special Call
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
GL
Transcript : Novartis AG - Shareholder/Analyst Call
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
GL
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
GL
Transcript : Novartis AG Presents at 2023 American Society of Clinical Oncology Annual Meeting, Jun-04-2023 07:00 PM
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
GL
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
GL
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
GL
Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
GL
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
GL
Transcript : Novartis AG - Special Call
AXCELLA HEALTH INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Axcella Health Inc. Announces Management Changes
CI
NOVARTIS : Pursuing a leaner organisational structure
Alphavalue
Transcript : Novartis AG - Special Call
Novartis to save at least $1 billion by 2024 thanks to simplified structure
RE
Novartis AG Announces Executive Changes
CI
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
BU
Transcript : Dicerna Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 09, 2021
 Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
BU
Dicerna Pharmaceuticals : Announces Results for PHYOX4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
AQ
Dicerna Pharmaceuticals : Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
BU
Dicerna Pharmaceuticals : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
AQ
Dicerna Pharmaceuticals : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
BU
Transcript : Dicerna Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 09, 2021
Transcript : Dicerna Pharmaceuticals, Inc. - Special Call
Dicerna Pharmaceuticals : Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
BU
Dicerna Pharmaceuticals : Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
BU
Dicerna Pharmaceuticals : Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
BU
Dicerna Pharmaceuticals : Announces Dosing Completion in Nedosiran PHYOX4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
AQ
Dicerna Pharmaceuticals : Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
BU
AXCELLA HEALTH INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Transcript : Dicerna Pharmaceuticals, Inc., Q1 2021 Earnings Call, May 06, 2021
Transcript : Dicerna Pharmaceuticals, Inc. - Special Call
Dicerna Pharmaceuticals : Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection
BU
Transcript : Dicerna Pharmaceuticals, Inc., 2020 Earnings Call, Feb 25, 2021
Dicerna Pharmaceuticals : Initiates PHYOX™4 Trial of Nedosiran for Primary Hyperoxaluria Type 3
BU
Dicerna Pharmaceuticals : Announces Enrollment Completion of PHYOX2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
AQ
Dicerna Pharmaceuticals : Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
BU
Dicerna Pharmaceuticals : Announces Positive Updated Data from Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus Infection
AQ
Dicerna Pharmaceuticals : Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
BU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Shreeram Aradhye
  4. News